Abstract
Histone deacetylase inhibitors are nowadays considered as promising anti-cancer drugs, as they interfere with several key steps of tumor development and progression, both in vitro and in vivo. Less attention has been paid to their impact on cell junctions. Nevertheless, cell junctions are gatekeepers in the management of tissue homeostasis, and their aberrant expression and functioning is observed in all aspects of cancer biology. The present review provides a state of the art of the current knowledge concerning the effects of histone deacetylase inhibitors on cell junctions. Besides an updated theoretical basis, we also exemplify its actual relevance in cancer therapy.
Keywords: histone deacetylase inhibitor, adherens junction, tight junction, gap junction, (hemi)desmosome, focal adhesion
Current Drug Targets
Title: Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Volume: 7 Issue: 6
Author(s): Mathieu Vinken, Papeleu Peggy, Rogiers Vera and Vanhaecke Tamara
Affiliation:
Keywords: histone deacetylase inhibitor, adherens junction, tight junction, gap junction, (hemi)desmosome, focal adhesion
Abstract: Histone deacetylase inhibitors are nowadays considered as promising anti-cancer drugs, as they interfere with several key steps of tumor development and progression, both in vitro and in vivo. Less attention has been paid to their impact on cell junctions. Nevertheless, cell junctions are gatekeepers in the management of tissue homeostasis, and their aberrant expression and functioning is observed in all aspects of cancer biology. The present review provides a state of the art of the current knowledge concerning the effects of histone deacetylase inhibitors on cell junctions. Besides an updated theoretical basis, we also exemplify its actual relevance in cancer therapy.
Export Options
About this article
Cite this article as:
Vinken Mathieu, Peggy Papeleu, Vera Rogiers and Tamara Vanhaecke, Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts, Current Drug Targets 2006; 7 (6) . https://dx.doi.org/10.2174/138945006777435281
DOI https://dx.doi.org/10.2174/138945006777435281 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Rapidly Changing Composition of the Global Street Drug Supply and its Effects on High-risk Groups for COVID-19
Current Psychopharmacology Histone Deacetylase Inhibitors and Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Delivery of siRNA to the Target Cell Cytoplasm: Photochemical Internalization Facilitates Endosomal Escape and Improves Silencing Efficiency, In Vitro and In Vivo
Current Pharmaceutical Design Human Papilloma Virus Vaccine Associated Uveitis
Current Drug Safety Inhibition of Aurora A Kinase by Alisertib Induces Autophagy and Cell Cycle Arrest and Increases Chemosensitivity in Human Hepatocellular Carcinoma HepG2 Cells
Current Cancer Drug Targets The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Application of Nanotechnology in the Diagnosis and Therapy of Hepatocellular Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Novel Glitazones with Diverse Peroxisome Proliferator Activated Receptor Modulatory Potential
Current Bioactive Compounds Target Driven Preclinical Screening for New Antimitotic Chemotherapy Agents
Current Topics in Medicinal Chemistry Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology
Recent Patents on DNA & Gene Sequences Lipid-Based Drug Delivery Systems for Cancer Treatment
Current Drug Targets Efficient Growth Inhibition of Human Osteosarcoma Cells Using a Peptide Derived from the MDM-2-Binding Site of p53
Protein & Peptide Letters Copper Complexes as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Novobiocin and Additional Inhibitors of the Hsp90 C-Terminal Nucleotide- binding Pocket
Current Medicinal Chemistry Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics DNA Damage-inducing Compounds: Unraveling their Pleiotropic Effects Using High Throughput Sequencing
Current Medicinal Chemistry Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Biological Function and Medicinal Research Significance of G-Quadruplex Interactive Proteins
Current Topics in Medicinal Chemistry Compound Ranking Based on a New Mathematical Measure of Effectiveness Using Time Course Data from Cell-Based Assays
Combinatorial Chemistry & High Throughput Screening